Icahn Says Future Is Big Pharma Will Buy Biotech (BIIB, AMLN)
More News related to AMLN
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
- FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
- Hapoalim Securities Upgrades Amylin (AMLN) to Hold; Two Important Milestones Achieved
More News related to BIIB
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease
More News related to Insiders' Blog
- RadioShack (RSH) iPhone News is a Game-Changer
- RIM Shares Lower as Susquehanna Downgrades to Neutral (RIMM)
- GE (GE), Comcast (CMCSA) Agree on Value for NBC Universal
Currently, my friend Mike Huckman is interviewing Carl Icahn over the phone on CNBC and asked him about what he plans to do with Biogen Idec (Nasdaq: BIIB) and Amylin (Nasdaq: AMLN). Icahn says he is not looking to sell Biogen Idec and Amylin Pharmaceuticals anytime soon. First, management needs to streamline things and get both of their operations in order.
Related Categories
Insiders' BlogRumors
Stocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
